Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Efficacy and Safety Trial of Rimegepant for Migraine Prevention in Adults
NCT03732638 · View on ClinicalTrials.gov ↗
Study Summary
The purpose of this is study is to compare the efficacy of BHV-3000 (rimegepant) to placebo as a preventive treatment for migraine, as measured by the reduction in the number of migraine days per month.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Rimegepant
Study Locations (20)
California
- Anaheim Clinical Trials — Anaheim
- Axiom Research, LLC — Apple Valley
- Axiom Research, LLC — Colton
- eStudySite — La Mesa
- Synergy San Diego — Lemon Grove
- Collaborative Neuroscience Network, LLC — Long Beach
- Pacific Research Partners, LLC — Oakland
- Artemis Institute for Clinical Research — San Diego
- Optimus Medical Group — San Francisco
- Artemis Institute for Clinical Research — San Marcos
- Neurological Research Institute — Santa Monica
- California Neuroscience Research Medical Group — Sherman Oaks
Arizona
- MDFirst Research-Chandler — Chandler
- MedPharmics, LLC — Phoenix
- Tucson Neuroscience Research — Tucson
Florida
- Riverside Clinical Research — Edgewater
- Galiz Research — Hialeah
- Multi-Specialty Research Associates, Inc. — Lake City
Arkansas
- Baptist Health Center for Clinical Research — Little Rock
Connecticut
- Ki Health Partners, LLC, dba New England Institute for Clinical Research — Stamford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,590 participants |
| Start Date | 2018-11-14 |
| Est. Completion | 2021-02-02 |
| Phase | Phase 2 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03732638
The ClinicalTrials.gov registry entry for NCT03732638 describes a study currently listed as completed. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 1,590 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 769 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Migraine appearing as the primary indexed condition, and to 2 interventions — of which Placebo is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT03732638 reports 20 study locations spanning 5 distinct geographic areas — top geographies include California, Arizona, Florida. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT03732638 about?
NCT03732638 is a clinical study titled "Efficacy and Safety Trial of Rimegepant for Migraine Prevention in Adults". The purpose of this is study is to compare the efficacy of BHV-3000 (rimegepant) to placebo as a preventive treatment for migraine, as measured by the reduction in the number of migraine days per month.
What is the current status of trial NCT03732638?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,590 participants. The study started on 2018-11-14. Estimated completion is 2021-02-02.
What conditions does trial NCT03732638 study?
This clinical trial studies the following conditions: Migraine. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT03732638?
The interventions under investigation include: Placebo (DRUG), Rimegepant (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT03732638?
This trial is sponsored by Pfizer, which has 769 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT03732638 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.